EGFR and central nervous system cancer: Such an approach is clinically feasible as reported in two recent phase II trial [28],[42]: herein, recurrent gliomas were treated for 5 to 7 days with gefitinib or erlotinib before surgery and resected tissues were evaluated for EGFR-dependent phosphoproteins.